Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Martin Cannon

Concepts (301)

Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Dendritic Cells
27
2025
136
4.480
Why?
Ovarian Neoplasms
24
2025
460
4.280
Why?
Cancer Vaccines
13
2020
78
2.880
Why?
Immunotherapy
13
2025
244
2.670
Why?
Th17 Cells
3
2020
27
1.440
Why?
Antigens, Neoplasm
11
2019
147
1.280
Why?
Myxoma virus
2
2025
15
1.150
Why?
Oncolytic Virotherapy
2
2025
21
1.150
Why?
CD4-Positive T-Lymphocytes
8
2023
165
1.030
Why?
Oncolytic Viruses
1
2025
13
0.960
Why?
Uterine Cervical Neoplasms
13
2011
299
0.910
Why?
Oncogene Proteins, Viral
7
2011
54
0.780
Why?
Neoplasm Recurrence, Local
3
2020
643
0.730
Why?
T-Lymphocytes, Regulatory
6
2011
84
0.700
Why?
T-Lymphocytes, Cytotoxic
12
2013
65
0.680
Why?
Indoleamine-Pyrrole 2,3,-Dioxygenase
3
2014
14
0.630
Why?
Lymphocytes, Tumor-Infiltrating
4
2019
78
0.590
Why?
CD8-Positive T-Lymphocytes
11
2023
132
0.540
Why?
Neoplasms
4
2019
1308
0.540
Why?
Antibodies, Monoclonal
5
2019
478
0.530
Why?
DNA-Binding Proteins
5
2007
426
0.530
Why?
Interleukin-17
2
2020
35
0.520
Why?
Adjuvants, Immunologic
4
2025
52
0.500
Why?
p38 Mitogen-Activated Protein Kinases
2
2014
95
0.500
Why?
Female
43
2025
28262
0.440
Why?
Ascites
1
2014
32
0.430
Why?
T-Lymphocytes
5
2017
329
0.430
Why?
Cell Line, Tumor
14
2025
1436
0.430
Why?
Immunologic Surveillance
2
2011
10
0.420
Why?
Humans
54
2025
52593
0.390
Why?
Cytokines
4
2014
626
0.390
Why?
Carcinoma
2
2017
137
0.380
Why?
Signal Transduction
3
2017
1714
0.380
Why?
T-Lymphocytes, Helper-Inducer
2
2011
42
0.370
Why?
Immunotherapy, Active
1
2011
4
0.370
Why?
Serine Endopeptidases
3
2009
50
0.360
Why?
Cytotoxicity, Immunologic
7
2011
57
0.360
Why?
Animals
17
2025
13507
0.330
Why?
Adoptive Transfer
1
2009
29
0.310
Why?
Immunotherapy, Adoptive
3
2005
167
0.300
Why?
Interferon-gamma
7
2020
179
0.290
Why?
Epitopes, T-Lymphocyte
3
2008
26
0.280
Why?
Mice
10
2025
5958
0.270
Why?
Lymphocyte Activation
3
2005
163
0.270
Why?
Papillomavirus Vaccines
1
2007
69
0.260
Why?
Herpesvirus 4, Human
2
2005
44
0.260
Why?
Immunodominant Epitopes
2
2008
9
0.260
Why?
Dependovirus
3
2011
103
0.230
Why?
Virus Replication
1
2025
150
0.220
Why?
HLA-A2 Antigen
3
2009
11
0.210
Why?
Cell Transformation, Viral
1
2003
25
0.200
Why?
Cell Line, Transformed
1
2003
74
0.200
Why?
Poxviridae Infections
1
2022
4
0.200
Why?
Poxviridae
1
2022
7
0.200
Why?
Interferon Type I
1
2022
28
0.190
Why?
Cystadenocarcinoma, Serous
5
2009
73
0.190
Why?
Vaccination
4
2010
299
0.190
Why?
Papillomavirus E7 Proteins
5
2011
32
0.190
Why?
Disease-Free Survival
2
2020
464
0.190
Why?
Interleukin-10
2
2017
84
0.190
Why?
Receptor, erbB-2
4
2008
80
0.190
Why?
Genes, MHC Class I
3
2008
11
0.180
Why?
Flow Cytometry
8
2013
400
0.180
Why?
Testis
2
2011
72
0.170
Why?
Membrane Proteins
4
2011
337
0.170
Why?
Injections, Intradermal
1
2020
14
0.170
Why?
Macrophages
4
2022
379
0.170
Why?
Immunity, Humoral
1
2020
23
0.170
Why?
Coculture Techniques
3
2014
145
0.170
Why?
Folate Receptor 1
1
2020
27
0.170
Why?
Cell Movement
2
2019
276
0.160
Why?
Enzyme-Linked Immunosorbent Assay
2
2013
237
0.160
Why?
Carcinoma, Hepatocellular
1
2022
200
0.160
Why?
Carcinoma, Lewis Lung
1
2019
10
0.160
Why?
B-Lymphocytes
5
2017
180
0.160
Why?
Melanoma, Experimental
1
2019
34
0.160
Why?
Repressor Proteins
3
2011
154
0.160
Why?
Self Tolerance
1
2019
1
0.160
Why?
Costimulatory and Inhibitory T-Cell Receptors
1
2019
1
0.160
Why?
Liver Neoplasms
1
2022
332
0.150
Why?
Transplantation, Autologous
1
2020
488
0.150
Why?
Aged
12
2020
10191
0.150
Why?
Cells, Cultured
6
2014
1588
0.140
Why?
Cytotoxicity Tests, Immunologic
4
2005
26
0.140
Why?
N-Acetylglucosaminyltransferases
1
2017
14
0.140
Why?
Programmed Cell Death 1 Receptor
1
2017
41
0.140
Why?
Receptors, Notch
1
2017
28
0.130
Why?
HLA Antigens
4
2006
56
0.130
Why?
Middle Aged
16
2020
13096
0.130
Why?
Human Umbilical Vein Endothelial Cells
2
2014
102
0.130
Why?
Neoplastic Stem Cells
1
2017
93
0.130
Why?
Carcinoma, Papillary
3
2005
51
0.130
Why?
Poliovirus Vaccine, Oral
2
2005
4
0.120
Why?
Genetic Vectors
3
2011
130
0.120
Why?
Poliovirus
2
2005
10
0.120
Why?
Neoplasm Proteins
1
2017
328
0.120
Why?
Adult
15
2011
14170
0.120
Why?
Clinical Trials, Phase I as Topic
1
2015
24
0.120
Why?
Adenocarcinoma
3
2004
404
0.110
Why?
Galectin 3
1
2014
14
0.110
Why?
Antigen Presentation
5
2009
26
0.110
Why?
Kallikreins
2
2005
19
0.110
Why?
Neoplasm Invasiveness
3
2017
278
0.110
Why?
Cystadenocarcinoma, Papillary
2
2005
14
0.110
Why?
Histocompatibility Antigens Class I
2
2005
48
0.110
Why?
Peptide Fragments
4
2009
210
0.110
Why?
Endometrial Neoplasms
2
2005
144
0.100
Why?
Uterine Neoplasms
2
2005
59
0.100
Why?
Papillomavirus Infections
3
2011
172
0.100
Why?
Mutation
1
2019
1344
0.100
Why?
Mice, Inbred C57BL
3
2017
1900
0.100
Why?
Intracellular Signaling Peptides and Proteins
2
2022
137
0.100
Why?
Lymphocytes
1
2013
149
0.090
Why?
Antigens, Viral
3
2007
43
0.090
Why?
V-Set Domain-Containing T-Cell Activation Inhibitor 1
1
2011
4
0.090
Why?
Killer Cells, Natural
4
2005
115
0.090
Why?
rho GTP-Binding Proteins
1
2011
8
0.090
Why?
Clonal Anergy
1
2011
13
0.090
Why?
A Kinase Anchor Proteins
1
2011
3
0.090
Why?
Calmodulin-Binding Proteins
1
2011
10
0.090
Why?
Antigen-Presenting Cells
1
2011
22
0.090
Why?
Antigens, Surface
1
2011
38
0.090
Why?
Drug Resistance, Neoplasm
5
2017
327
0.090
Why?
Human papillomavirus 16
1
2011
44
0.090
Why?
Antineoplastic Agents, Alkylating
1
2011
77
0.090
Why?
Immunity, Cellular
2
2008
64
0.090
Why?
Uterine Cervical Dysplasia
1
2011
51
0.090
Why?
Cyclophosphamide
1
2011
172
0.090
Why?
Prostate
1
2011
117
0.080
Why?
Diphosphonates
1
2011
92
0.080
Why?
Imidazoles
1
2011
124
0.080
Why?
Gene Expression Regulation, Neoplastic
4
2011
857
0.080
Why?
Papillomaviridae
3
2005
105
0.080
Why?
Phenotype
1
2013
800
0.080
Why?
Neoplasm Staging
3
2007
768
0.080
Why?
Gene Expression Profiling
2
2005
1110
0.080
Why?
K562 Cells
2
2008
41
0.080
Why?
Carrier Proteins
1
2011
320
0.080
Why?
Tumor Microenvironment
2
2023
255
0.080
Why?
CA-125 Antigen
1
2008
16
0.080
Why?
Immediate-Early Proteins
1
2008
18
0.070
Why?
Cytomegalovirus
1
2008
30
0.070
Why?
Green Fluorescent Proteins
1
2008
88
0.070
Why?
RNA, Messenger
4
2005
1139
0.070
Why?
Interleukin-4
2
2005
44
0.070
Why?
Antibody Formation
1
2007
51
0.070
Why?
Prostatic Neoplasms
1
2011
400
0.070
Why?
Antibodies, Viral
1
2007
110
0.070
Why?
Amino Acid Sequence
2
2005
574
0.070
Why?
RNA Interference
2
2017
186
0.070
Why?
Molecular Sequence Data
2
2005
773
0.070
Why?
Ovary
3
2017
107
0.070
Why?
Oligonucleotide Array Sequence Analysis
2
2005
412
0.060
Why?
Recombinant Proteins
1
2007
496
0.060
Why?
Hypersensitivity, Delayed
1
2005
18
0.060
Why?
Breast Neoplasms
3
2003
1205
0.060
Why?
Monocytes
2
2022
129
0.060
Why?
Neoplasms, Squamous Cell
1
2005
7
0.060
Why?
Electroporation
1
2005
18
0.060
Why?
Cell Line
4
2010
1033
0.060
Why?
Poliomyelitis
1
2005
5
0.060
Why?
Enterotoxins
1
2005
12
0.060
Why?
Gene Transfer Techniques
1
2005
42
0.060
Why?
Interleukin-12
1
2005
27
0.060
Why?
Reverse Transcriptase Polymerase Chain Reaction
4
2008
582
0.060
Why?
Genes, erbB-2
1
2005
8
0.060
Why?
Immunologic Memory
1
2005
32
0.060
Why?
Antigens, Heterophile
1
2005
1
0.060
Why?
Plasmodium falciparum
1
2005
23
0.060
Why?
Burkitt Lymphoma
1
2005
27
0.060
Why?
Endemic Diseases
1
2005
25
0.060
Why?
Malaria, Falciparum
1
2005
21
0.060
Why?
Epstein-Barr Virus Infections
1
2005
33
0.060
Why?
Gangliosides
1
2004
5
0.060
Why?
Ascitic Fluid
1
2004
13
0.060
Why?
Proteins
2
2005
354
0.060
Why?
Genetic Therapy
1
2005
122
0.060
Why?
Ovariectomy
1
2004
113
0.060
Why?
Vaccines, Subunit
1
2004
15
0.050
Why?
Hysterectomy
1
2004
91
0.050
Why?
Immunization, Passive
1
2004
29
0.050
Why?
Interleukin-6
1
2005
277
0.050
Why?
Clinical Trials as Topic
2
2007
472
0.050
Why?
Tumor Necrosis Factor-alpha
2
2019
396
0.050
Why?
Cell Differentiation
2
2004
673
0.050
Why?
Protein Binding
1
2005
673
0.050
Why?
Epithelial Cells
1
2005
215
0.050
Why?
Vesiculovirus
1
2022
6
0.050
Why?
Vaccinia virus
1
2022
6
0.050
Why?
Virus Latency
1
2003
53
0.050
Why?
Host Specificity
1
2022
5
0.050
Why?
Cell Adhesion Molecules
1
2003
88
0.050
Why?
Cell Communication
1
2003
72
0.050
Why?
Nucleotidyltransferases
1
2022
15
0.050
Why?
Mammals
1
2022
60
0.050
Why?
Disease Models, Animal
2
2022
1486
0.050
Why?
Tumor Cells, Cultured
4
2003
448
0.050
Why?
Xenograft Model Antitumor Assays
2
2017
222
0.050
Why?
Down-Regulation
1
2003
344
0.050
Why?
Rabbits
1
2022
373
0.050
Why?
Blood Transfusion
1
2002
129
0.050
Why?
Radiotherapy
1
2002
129
0.050
Why?
Disease Progression
2
2019
873
0.050
Why?
Viral Proteins
1
2022
164
0.040
Why?
Immunohistochemistry
4
2005
984
0.040
Why?
Carcinoma, Squamous Cell
1
2004
331
0.040
Why?
Transcriptome
1
2022
368
0.040
Why?
Endothelium
1
2019
38
0.040
Why?
Intercellular Adhesion Molecule-1
1
2019
59
0.040
Why?
Gene Expression
3
2008
623
0.040
Why?
Antineoplastic Combined Chemotherapy Protocols
1
2004
1031
0.040
Why?
Injections, Intraperitoneal
2
2010
57
0.040
Why?
Tissue Banks
1
2017
9
0.030
Why?
Mice, Inbred NOD
1
2017
92
0.030
Why?
STAT3 Transcription Factor
1
2017
87
0.030
Why?
Antibodies, Monoclonal, Humanized
3
2004
237
0.030
Why?
Glycosylation
1
2017
104
0.030
Why?
Tumor Burden
1
2017
136
0.030
Why?
RNA, Small Interfering
1
2017
218
0.030
Why?
Multiple Myeloma
1
2011
3050
0.030
Why?
Protein Processing, Post-Translational
1
2017
153
0.030
Why?
Kaplan-Meier Estimate
1
2017
485
0.030
Why?
Lung Neoplasms
1
2002
634
0.030
Why?
Survival Analysis
2
2010
673
0.030
Why?
Apoptosis
2
2014
1121
0.030
Why?
Perforin
2
2005
12
0.030
Why?
Pore Forming Cytotoxic Proteins
2
2005
11
0.030
Why?
Neovascularization, Pathologic
1
2014
158
0.030
Why?
Anti-Bacterial Agents
1
2019
803
0.030
Why?
Interleukin-2
2
2003
69
0.030
Why?
Membrane Glycoproteins
2
2005
242
0.020
Why?
Vaginal Smears
1
2011
28
0.020
Why?
Organ Specificity
1
2011
117
0.020
Why?
Prostate-Specific Antigen
1
2011
44
0.020
Why?
DNA, Viral
1
2011
138
0.020
Why?
Time Factors
2
2010
3000
0.020
Why?
Major Histocompatibility Complex
1
2010
13
0.020
Why?
Prognosis
2
2005
2118
0.020
Why?
Transduction, Genetic
1
2008
44
0.020
Why?
Fluorescent Antibody Technique
1
2008
111
0.020
Why?
Leukocytes, Mononuclear
1
2008
122
0.020
Why?
Alphapapillomavirus
1
2007
13
0.020
Why?
T-Lymphocyte Subsets
1
2007
41
0.020
Why?
Models, Immunological
1
2007
8
0.020
Why?
Aged, 80 and over
2
2005
3420
0.020
Why?
Immune Tolerance
1
2007
91
0.020
Why?
Adolescent
2
2011
6737
0.020
Why?
HLA-B Antigens
1
2006
8
0.020
Why?
Clone Cells
1
2006
76
0.020
Why?
Immunity, Innate
1
2007
117
0.020
Why?
Male
3
2011
26863
0.020
Why?
Combined Modality Therapy
1
2007
639
0.020
Why?
Claudin-3
1
2005
5
0.020
Why?
Claudin-4
1
2005
7
0.010
Why?
Mice, Inbred C3H
1
2005
82
0.010
Why?
Protein Sorting Signals
1
2005
8
0.010
Why?
Protein Engineering
1
2005
18
0.010
Why?
Peptides
1
2006
236
0.010
Why?
Histocompatibility Antigens Class II
1
2005
34
0.010
Why?
Plasmids
1
2005
167
0.010
Why?
Species Specificity
1
2005
191
0.010
Why?
Mice, SCID
1
2005
182
0.010
Why?
Protein Folding
1
2005
61
0.010
Why?
Epithelium
1
2004
65
0.010
Why?
Endocytosis
1
2005
55
0.010
Why?
Receptors, Cell Surface
1
2005
113
0.010
Why?
Carboplatin
1
2004
57
0.010
Why?
Radiotherapy, Adjuvant
1
2004
64
0.010
Why?
Paclitaxel
1
2004
91
0.010
Why?
Polymerase Chain Reaction
1
2005
460
0.010
Why?
Transfection
1
2005
369
0.010
Why?
Antineoplastic Agents, Hormonal
1
2004
53
0.010
Why?
Antibody-Dependent Cell Cytotoxicity
1
2003
12
0.010
Why?
Tumor Stem Cell Assay
1
2003
17
0.010
Why?
Proportional Hazards Models
1
2005
444
0.010
Why?
Cervix Uteri
1
2004
49
0.010
Why?
Up-Regulation
1
2005
462
0.010
Why?
Swine
1
2005
427
0.010
Why?
Kinetics
1
2005
622
0.010
Why?
Keratinocytes
1
2004
93
0.010
Why?
Receptors, Interleukin-2
1
2002
6
0.010
Why?
Lymphocyte Subsets
1
2002
14
0.010
Why?
Cell Culture Techniques
1
2003
99
0.010
Why?
Receptors, Antigen, T-Cell
1
2003
51
0.010
Why?
Leukocytes
1
2003
60
0.010
Why?
Antigens, CD19
1
2002
28
0.010
Why?
Receptors, IgG
1
2002
24
0.010
Why?
Cell Death
1
2003
175
0.010
Why?
Doxorubicin
1
2004
241
0.010
Why?
Immunophenotyping
1
2002
117
0.010
Why?
Cisplatin
1
2004
285
0.010
Why?
Survival Rate
1
2005
952
0.010
Why?
Antibodies, Monoclonal, Murine-Derived
1
2002
47
0.010
Why?
Tumor Virus Infections
1
2002
48
0.010
Why?
Fatal Outcome
1
2002
196
0.010
Why?
Young Adult
1
2011
4337
0.010
Why?
Cell Division
1
2002
288
0.010
Why?
Case-Control Studies
1
2004
1202
0.010
Why?
Prospective Studies
1
2004
2457
0.010
Why?
Risk Factors
1
2004
3952
0.010
Why?
Antineoplastic Agents
1
2002
1221
0.010
Why?
Cannon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description